Principia Biopharma, Inc.

Read more
Martin Babler's photo - President & CEO of Principia Biopharma, Inc.

President & CEO

Martin Babler

CEO Approval Rating

85/100

Founded:

2008

Status:

PublicSubsidiary of Sanofi S.ANASDAQPRNB

PRINCIPIA BIOPHARMA, INC. TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Innovimmune Biotherapeutics is seen as one of Principia Biopharma, Inc.'s top competitors. Innovimmune Biotherapeutics's headquarters is in New York, New York, and was founded in 2010. Like Principia Biopharma, Inc., Innovimmune Biotherapeutics also works within the Biotechnology industry. Innovimmune Biotherapeutics generates 50% of Principia Biopharma, Inc.'s revenue.

ASLAN Pharmaceuticals is one of Principia Biopharma, Inc.'s top rivals. ASLAN Pharmaceuticals was founded in 2010, and its headquarters is in Singapore, Central Singapore. Like Principia Biopharma, Inc., ASLAN Pharmaceuticals also works within the Biotechnology field. ASLAN Pharmaceuticals has 51 fewer employees than Principia Biopharma, Inc..

Clovis Oncology is Principia Biopharma, Inc.'s #3 rival. Clovis Oncology is a Public company that was founded in 2009 in Boulder, Colorado. Like Principia Biopharma, Inc., Clovis Oncology also competes in the Biotechnology sector. Compared to Principia Biopharma, Inc., Clovis Oncology has 360 more employees.

Principia Biopharma, Inc. Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$20M

Principia Biopharma, Inc.'s revenue is the ranked 13th among it's top 10 competitors. The top 10 competitors average 10.7B. Over the last two quarters, Principia Biopharma, Inc.'s revenue has grown by 66.7%. Specifically, in Q2 2020's revenue was $50M; in Q2 2019, it was $30M.

Principia Biopharma, Inc. Acquisitions

No recent acquisitions found related to Principia Biopharma, Inc.

Principia Biopharma, Inc. Funding History

Since Principia Biopharma, Inc. was founded in 2008, it has participated in 6 rounds of funding. In total Principia Biopharma, Inc. has raised $246.2M. Principia Biopharma, Inc.'s last funding round was on Sep 2018 for a total of $106.2M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Sep 2018
$106.3M
-
Equity
Aug 2018
$50M
-
Equity
Jul 2015
$15.3M
Series B
Apr 2014
$50M
Series A
Oct 2012
$12.5M

Since Principia Biopharma, Inc. was founded in 2008, it has participated in 6 rounds of funding. In total Principia Biopharma, Inc. has raised $246.2M. Principia Biopharma, Inc.'s last funding round was on Sep 2018 for a total of $106.2M

Principia Biopharma, Inc. Investments

No recent investments found related to Principia Biopharma, Inc.

Principia Biopharma, Inc. News

September 14, 2020Micro Small Cap

Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - ONDK, PRNB, VRTU, IMMU

NEW YORK, NY / ACCESSWIRE / September 14, 2020 / Halper Sadeh LLP, a global investor rights law firm,... See more »
September 1, 2020The Business Journals: San Francisco Business Times

Inside a biotech's buyout for 32% more than the initial offer

Over three months, tiny Principia Biopharma moved discussions with Sanofi from a one-drug deal to a c... See more »
August 31, 2020Pharmabiz

Sanofi commences tender offer to acquire all outstanding shares of biopharma company, Principia Biopharma

Sanofi, global biopharmaceutical company, commences a tender offer (the "Offer") to acquire all of th... See more »
August 28, 2020FinanzNachrichten

Sanofi To Commence Tender Offer To Acquire Principia Biopharma

PARIS (dpa-AFX) - Sanofi (SNYNF, SNY), on Friday, said it intends to commence a tender offer to acqui... See more »
August 21, 2020MarketScreener

Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Principia Biopharma Inc. - PRNB

(marketscreener.com) Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm... See more »
August 20, 2020Markets Insider

Moore Kuehn Encourages NTN, PRNB, MNTA, and PFNX Investors to Contact Law Firm | Markets Insider

NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigati... See more »
August 18, 2020MarketScreener

Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Are Shareholders Getting a Fair Price?

(marketscreener.com) SAN DIEGO, Aug. 18, 2020 -- Shareholder rights law firm Johnson Fistel, LLP has ... See more »

Principia Biopharma, Inc. Press Releases

June 23, 2020StreetInsider

Principia Announces First Patient Enrolled in Sanofi's Phase 3 Trial of SAR442168 in Relapsing Multiple Sclerosis

Dosing of Patient Will Trigger $50 Million Milestone PaymentSOUTH SAN FRANCISCO, Calif., June 23, 202... See more »
June 3, 2020StreetInsider

Beyond B Cells and Antibodies

Event scheduled for 4:00 pm ET on Tuesday, June 16thSOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOB... See more »
May 6, 2020GlobeNewswire

Principia Biopharma Reports First Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB)... See more »
January 9, 2020centralcharts

Principia Announces Expansion of its BTK Franchise with PRN473 Topical

Company expands focus on immune-mediated diseases and suspends FGFR program Company outlines anticipa... See more »
January 7, 2020centralcharts

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases

Company's lead candidate PRN1008 receives generic name -- rilzabrutinib Rilzabrutinib to enter clinic... See more »
November 13, 2019centralcharts

Principia to Present at the Stifel Healthcare Conference 2019

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB... See more »
November 5, 2019GlobeNewswire

Principia Biopharma Reports Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB... See more »

Principia Biopharma, Inc. Videos

Social Media

Principia Biopharma, Inc. Headquarters

220E Grand Avenue

South San Francisco, California94080

650-416-7700

Driving Directions »

Trending Companies

Principia Biopharma, Inc. Summary

ABOUT

Overview

Principia is a biopharmaceutical company that develops small molecule drugs for the treatment of immune-mediated diseases. Principia Biopharma, Inc. was founded in 2008. Principia Biopharma, Inc.'s headquarters is located in South San Francisco, Calif...

CEO

Principia Biopharma, Inc.'s President & CEO, Martin Babler, currently has an approval rating of 85%. Principia Biopharma, Inc.'s primary competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals & Clovis Oncology.

Frequently Asked Questions about Principia Biopharma, Inc.

  1. When was Principia Biopharma, Inc. founded?

    Principia Biopharma, Inc. was founded in 2008
  2. Who is Principia Biopharma, Inc.'s CEO?

    Principia Biopharma, Inc.'s CEO is Martin Babler
  3. How much revenue does Principia Biopharma, Inc. generate?

    Principia Biopharma, Inc. generates $20M in revenue
  4. How much funding does Principia Biopharma, Inc. have?

    Principia Biopharma, Inc. has historically raised $246.2M in funding
  1. Where is Principia Biopharma, Inc.'s headquarters?

    Principia Biopharma, Inc.'s headquarters is in South San Francisco California, USA
  2. How many employees does Principia Biopharma, Inc. have?

    Principia Biopharma, Inc. has 69 employees
  3. What sector does Principia Biopharma, Inc. operate in?

    Principia Biopharma, Inc. is in Biotechnology
  4. Who are Principia Biopharma, Inc.'s competitors?

    Principia Biopharma, Inc.'s top competitors are Innovimmune Biotherapeutics, ASLAN Pharmaceuticals, Clovis Oncology